Vaccine trial for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized vaccine made from your own tumor cells for advanced colorectal cancer that is mismatch repair proficient (pMMR). It aims to see if the vaccine can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced colorectal cancer that is pMMR type.
- Standard treatments have failed, caused side effects, or you cannot take them.
- You have at least one tumor that can be measured on scans.
- You are in fairly good health (able to care for yourself, up and about more than half the day).
- Your blood counts and organ function (kidney, liver, heart) are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) that are trained to recognize colorectal cancer. It is for people who had surgery for colorectal cancer that spread to the liver and are now at high risk for the cancer returning.
This trial tests a new vaccine (YMN-136) for people with colorectal cancer that has spread to the liver and hasn't responded to at least three prior treatments. The goal is to see if the vaccine can help control the cancer.
This trial tests a sequence of treatments for people with a specific type of advanced colorectal cancer (called pMMR or MSS) that has not responded to earlier therapies. Patients first receive an immunotherapy combination (pembrolizumab plus a personalized dendritic cell vaccine) followed by a chemotherapy pill (trifluridine/tipiracil) plus bevacizumab. The goal is to see if this sequence can help control the cancer.
This trial tests a custom-made vaccine designed from your tumor's genetic material. The vaccine is given alongside standard chemotherapy and an immunotherapy drug to try to prevent the cancer from coming back. It is for people with stage 3 colorectal cancer that has been fully removed by surgery and has certain high-risk features.
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
Hear when a new pMMR/MSS Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.